Sanofi, Formation Bio and OpenAI Forge First-in-class AI Collaboration
In a forward-thinking move, Sanofi, Formation Bio, and OpenAI have joined forces to harness the power of artificial intelligence in expediting the drug development process. This ambitious collaboration aims to construct sophisticated AI-driven software designed to streamline the creation of new treatments, thereby delivering them to patients with unprecedented efficiency.
The tripartite alliance will integrate a wealth of data, cutting-edge software, and finely-tuned AI models to craft bespoke solutions tailored to various stages of the drug development journey. This initiative marks a pioneering collaboration within the pharmaceutical and life sciences sectors, setting a new standard for innovation and potentially transforming the landscape of medicine as we know it.
Sanofi will leverage the new partnership to provide access to proprietary data to develop AI models as it continues on its path to becoming the first biopharma company powered by AI at scale.
Paul Hudson, CEO, Sanofi, said:
“This unique collaboration is the next significant step in our journey to becoming a pharmaceutical company substantially powered by AI. Next generation, first-of-its kind AI model customizations will be an important foundation in our efforts to shape the future of drug development for pharma and for the many patients waiting for innovative treatments.”
OpenAI, the world leader in AI technology behind ChatGPT and DALL-E, will contribute access to cutting-edge AI capabilities, including the ability to fine-tune models, deep AI expertise and dedicated thought partnership and resources.
Brad Lightcap, COO, OpenAI, stated:
“There is massive potential for AI to accelerate drug development. We are excited to collaborate with Sanofi and Formation Bio to help patients and their families by bringing new medicines to market.”
Formation Bio, an AI and tech-driven drug developer with its own pipeline of drug assets, will provide extensive engineering resources, experience operating at the intersection of pharma and AI, and its tech-driven development platform to design, develop and deploy AI technologies across all aspects of the pharma lifecycle.
Benjamine Liu, Co-Founder & CEO, Formation Bio, commented:
“I firmly believe that by combining our strengths, Sanofi, OpenAI and Formation Bio can reimagine drug development in the pharma industry. By creating and implementing customized AI agents and models designed for our industry, companies like Sanofi and Formation Bio can begin to scale with unprecedented productivity and transform the pace at which we bring new medicines to patients.”
The potential positive impact of AI for patients waiting for new treatments could be tremendous and Sanofi, Formation Bio and OpenAI plan to lead the way for drug developers.
Recommended Companies
More Headlines
